Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

Running, not enrolling

Conditions studied: Hematologic Malignancy

In brief

The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.

Key facts

Study ID

NCT03890614

Run by

Wake Forest University Health Sciences

People needed

70

Starts

2019-05-16

Expected to finish

2027-02-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with suspected or confirmed hematologic malignancy undergoing a bone marrow biopsy as part of their care.
• The ability to understand and willingness to sign an IRB approved informed consent document.

Where it is running

• Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.